vetcbd teljes spektrumú olaj 10%
vitamed pharma kereskedelmi és szolgáltató kft. - kókuszolaj, cannabidiol (cbd olaj) - belsoleges emulziós cseppek - imidakloprid - kutya, macska
hemp arsenal teljes spektrumú cbd olaj lovaknak
hemp arsenal kft. - cannabidiol (cbd olaj) - belsoleges emulziós cseppek - detomidin - ló
arthrocol full spektrum cbd5 olaj
arthrocol kft. - cannabidiol (cbd olaj) - belsoleges emulziós cseppek - kutya
spectrum 10 hypro pac szorpakolás
innoreÁl kereskedelmi és szolgáltató kft. - külsoleges oldat - kutya, macska
spectrum one balzsam
innoreÁl kereskedelmi és szolgáltató kft. - krém - kutya, macska
spectrum one sampon
innoreÁl kereskedelmi és szolgáltató kft. - sampon - kutya, macska
spectrum one szortömeg építo sampon
innoreÁl kereskedelmi és szolgáltató kft. - sampon - kutya, macska
spectrum ten balzsam
innoreÁl kereskedelmi és szolgáltató kft. - krém - kutya, macska
spectrum ten sampon
innoreÁl kereskedelmi és szolgáltató kft. - sampon - kutya, macska
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - szelektív immunszuppresszánsok - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.